Comparison of two assessment tools of antidepressant side-effects: UKU scale versus spontaneous notification;Comparaison de deux outils de mesure des effets indésirables d'un traitement antidépresseur : La notification spontanée et l'échelle UKU

Encephale

Volumn 30, Issue 5, 2004, Pages 425-432

  Gruwez, B ^a   Gury, C ^b   Poirier, M F ^b   Bouvet, O ^b   Gerard A ^b   Bourdel, M C ^b   Bayle F J ^b   Olie J P ^b  

^a Hôpital Cochin ^*  (France)

^b CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

Antidepressant; Side effects; Spontaneous notification; UKU scale

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; HYPNOTIC AGENT; MILNACIPRAN; MIRTAZAPINE; NORADRENALIN UPTAKE INHIBITOR; NORADRENERGIC AND SPECIFIC SEROTONERGIC ANTIDEPRESSANT; PAROXETINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; AGED; AKATHISIA; AKINESIA; AMENORRHEA; ARTICLE; AUTONOMIC NEUROPATHY; BRADYCARDIA; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CONVULSION; DEPRESSION; DRUG DEPENDENCE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DYSTONIA; EUPHORIA; FEMALE; GALACTORRHEA; GYNECOMASTIA; HEART PALPITATION; HUMAN; HYPERKINESIA; HYPERSALIVATION; HYPOKINESIA; HYPOTENSION; LIBIDO DISORDER; MAJOR DEPRESSION; MALE; MELANCHOLIA; MENORRHAGIA; META ANALYSIS; MICTURITION DISORDER; MOOD DISORDER; NEUROTOXICITY; OUTPATIENT; PHOTOSENSITIVITY DISORDER; PIGMENT DISORDER; POLYDIPSIA; POLYURIA; RATING SCALE; RELIABILITY; SEXUAL DYSFUNCTION; SIDE EFFECT; SPONTANEOUS NOTIFICATION SCALE; STANDARDIZATION; UKU SCALE; WEIGHT REDUCTION;

EID: 8744280620     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0013-7006(04)95457-7     Document Type: Article

References (19)

1. AGENCE FRANÇAISE DE SÉCURITÉ SANITAIRE DES PRODUITS DE SANTÉ. Observatoire National des Prescriptions et Consommations des Médicaments. Répartition par produit des ventes d'antidépresseurs aux officines, chiffre d'affaire et prescriptions, 2000.
2. ANSSEAU M, PAPART P, TROISFONTAINES B et al. Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology 1994 ; 114 : 131-7.
3. BAYLÉ FJ, MISDRAHI D. Observance - facteurs d'observance-comment l'améliorer ? In : Du bon usage des psychotropes. Massot J, Martin P, eds. APNET (Association Pédagogique Nationale pour l'Enseignement de la Thérapeutique). Paris : Vigot, 2000.
4. BÉGAUD B. Analyse d'incidence en pharmacovigilance. Application à la notification spontanée. Bordeaux : Arme-Pharmacovigilance, 1991.
5. CASSIDY WL, FLANAGAN NB, SPELLMAN M et al. Clinical observations in manic depressive disease. JAMA 1957 ; 164 : 1535-46.
6. DALERY J, SECHTER D. Traitement prolongé par antidé presseur. Encephale 1994; XX: 209-14.
7. DEWANN MJ, ANAND VS. Evaluating the tolerability of the newer antidepressants. J Nerv Ment Dis 1999 ; 187 : 96-101.
8. EKSELIUS L, VON KNORRING L, EBERHARD G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 1997 ; 12 : 323-31.
9. GUELFI JD, PULL CB, GUELFI C et al. La CHESS : utilisation dans la pathologie anxieuse et dépressive. Structure factorielle. Ann Medico Psychol 1983 ; 141 : 257-78.
10. GUELFI JD. L'évaluation clinique standardisée en psychiatrie. Fabre P, ed. Paris : Système Nerveux Central, 1996.
11. GUELFIJD, ANSSEAU M, CORRUBLE E et al. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacol 1998 ; 13 : 121-8.
12. HAFFMANS PM, TIMMERMAN L, HOOGDUIN CA et al. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients : a double-blind, multicentre study. Int Clin Psychopharmacol 1996 ; 11 : 157-64.
13. IOANNIDIS JPA, LAU J. Completeness of safety reporting in randomized trials - an evaluation of 7 medical areas. JAMA 2001 ; 285 (4) : 437-43.
14. LE PAPE A, LECOMTE T. Prévalence et prise en charge médicale de la dépression en 1996-1997. Bulletin d'information en économie de la santé n° 21, CREDES, 1999.
15. LINGIAERDE O, AHLFORS UG, BECH P et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987 ; 76 (Suppl 334).
16. MONTEJO-GONZALES AL, LIORCAG, IZQUIERDO A et al. SSRI-induced sexual dysfunction : fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997 ; 23 (3) : 176-94. Review.
17. NELSON JC, JATLOW P, QUINLAN DM. Subjective complaints during desipramine treatment. Relative importance of plasma drug concentrations and the severity of depression. Arch Gen Psychiatry 1984 ; 41 : 55-9.
18. OLVER JS, BURROWS GD, NORMAN TR. Third-generation antidepressants : do they offer advantages over the SSRIs ? CNS Drugs 2001 ; 15 (12) : 941-54.
19. PATRIS M, BOUCHARD JM, BOUGEROL T et al. Citalopram versus fluoxetine : a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996 ; 11 : 129-36.